Business Context and Reporting Period
This Form 8-K was filed by Pieris Pharmaceuticals, Inc. on February 27, 2017. The filing reports the entry into a Material Definitive Agreement with ASKA Pharmaceutical Co., Ltd. regarding the drug candidate PRS-080, which targets hepcidin for the treatment of anemia.
Key Financial Metrics
The filing details specific financial terms of the new agreement but does not provide consolidated revenue, profit, cash flow, or balance sheet data for the company.
- Upfront Option Payment: $2.75 million USD to be received from ASKA.
- Potential Future Payments: More than $80 million USD in combined option exercise fees and milestone payments for the first indication in Japan.
- Royalties: Double-digit royalties on net sales, potentially reaching the mid- to high-teens percentage range.
Material Changes
The primary material change is the execution of an Exclusive Option Agreement granting ASKA the right to license PRS-080 for development and commercialization in Japan, South Korea, and certain other Asian markets (excluding China). This agreement is contingent upon the completion of a planned Phase 2a study in dialysis-dependent anemia patients.
Outlook, Risks, and Contingencies
Management Commentary and Outlook: The agreement is structured to allow ASKA to evaluate the drug's potential following the Phase 2a study results. If the option is exercised, Pieris anticipates significant milestone payments and ongoing royalty revenue.
Contingencies and Risks: The agreement is time-sensitive and contingent on study results. The option rights terminate on the earliest of the following:
- ASKA's written notice of non-exercise.
- ASKA's failure to exercise the option within 60 days of final Phase 2a results availability.
- Three months from the delivery of final Phase 2a results in the European Union.
- Execution of definitive license agreements.
The filing notes that the description of the agreement is qualified by the full text of the Option Agreement, which will be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2017.
Investor Verification Checklist
- Verify the receipt of the $2.75 million option payment in upcoming financial statements.
- Monitor the timeline and results of the Phase 2a study in dialysis-dependent anemia patients.
- Review the full Option Agreement text in the upcoming Form 10-Q for specific milestone triggers and royalty definitions.
- Confirm whether ASKA exercises the option within the specified 60-day window following study results.